IN THIS ISSUE

Breast cancer is the second most common type of cancer, but despite its wide-reaching impact, the number of deaths caused by the condition has fallen by almost 50% since the 1980s, according to Cancer Research UK. We take a look at how breast cancer oncology has developed over the past three decades. Plus, we investigate the decision to restricting PrEP access to a small pool of patients in the NHS England Impact Trial even though the same medication is freely available elsewhere in the UK.

In other news, we debate the viability of Democratic candidate Pete Buttigieg’s plan to tax Big Pharma, examine prominent issues patients face when undergoing endometriosis treatments, and track the rise of fake medicines in Africa as well as the organisations working to put a stop to the counterfeit drug trade.

Also, we explore the potential of off-the-shelf CAR-T therapies, review Nobel Prize-winning research into the ways that cells sense and adapt to oxygen availability, and find out why pharma industry bigwigs are pulling out all the stops to gain access to China’s pharma market.

Eloise McLennan, editor

Go to article: Home | Access denied: the Impact trial Go to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: NewsGo to article: FargoGo to article: The pharma industry briefingGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Breast cancer timeline: charting three decades of successGo to article: PrEP drugs: is the NHS letting down patients at risk of HIV?Go to article: Swiss WorldCargoGo to article: Debate: can US pharma be taxed into behaving?Go to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Can new therapies tackle the burden of endometriosis?Go to article: The rise of fake medicines in AfricaGo to article: Zenatek Go to article: Off-the-shelf CAR-T therapy: broadening the reach of precision medicineGo to article: Nobel Prize 2019: how a breathtaking discovery unlocked new drugsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: China in 2019: a prime destination for R&D deals Go to article: The global-local continuum: tips for a joined-up approach to Regulatory & PV outGo to article: Pharmacovigilance 2.0: reskilling for the digital & data science ageGo to article: Air France KLM Cargo Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue